Professor Robert Hawkins is a consultant medical oncologist specializing in adrenal cancer, kidney cancer, melanoma, and soft tissue cancer. He focuses on immunotherapy as a treatment for cancer, including high-dose interleukin-2 for renal cancer. Professor Hawkins undertakes Phase I/II trials of immune and other biological therapies in various cancers, including gastrointestinal cancers, melanoma, B cell lymphomas, and renal cancers. He leads the EU 'ATTACK' program and the EU 'ATTRACT' training network, linking European researchers in the engineered T-cell field. He has established a specialist Cellular Therapy Laboratory Unit supporting trials and treatments of cellular therapy for B-cell malignancies and melanoma. Professor Hawkins attended medical school at Cambridge University and University College London, then trained in medical oncology at the Royal Marsden and Addenbrooke's Hospitals. He holds a PhD in antibody engineering from the MRC Laboratory of Molecular Biology in Cambridge. His expertise includes immunotherapy, chemotherapy, renal cancer, adrenal cancer, melanoma, soft tissue cancer, and gastrointestinal cancers.